These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9156252)

  • 1. Fatal GVHD demonstrating an involvement of respiratory muscle following donor leukocyte transfusion (DLT).
    Oshima Y; Takahashi S; Nagayama H; Nishiwaki K; Kobayashi Y; Tojo A; Okamoto S; Tani K; Ozawa K; Wakabayashi T; Sato N; Kobayashi S; Nakamura K; Ohya Y; Nukina N; Kanazawa I; Asano S
    Bone Marrow Transplant; 1997 Apr; 19(7):737-40. PubMed ID: 9156252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation.
    Pati AR; Godder K; Lamb L; Gee A; Henslee-Downey PJ
    Bone Marrow Transplant; 1995 Jun; 15(6):979-81. PubMed ID: 7581101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testicular relapse of AML during chronic graft-versus-host disease induced by donor leukocyte infusion.
    Tringali S; Vasta S; Scimè R; Catania P; Cavallaro AM; Majolino I
    Haematologica; 1996; 81(4):339-42. PubMed ID: 8870379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Donor leukocyte transfusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation].
    Itoh T; Hatta Y; Miyajima T; Simojima H; Sawada U; Horie T
    Rinsho Ketsueki; 1998 Jun; 39(6):409-15. PubMed ID: 9695667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Skeletal muscle pathology of chronic graft versus host disease accompanied with myositis, affecting predominantly respiratory and distal muscles, and hemosiderosis].
    Oya Y; Kobayashi S; Nakamura K; Shimizu J; Murayama S; Kanazawa I
    Rinsho Shinkeigaku; 2001 Sep; 41(9):612-6. PubMed ID: 11968747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic effect of donor leukocyte transfusion in relapsing marrow transplants in Japan].
    Shiobara S; Takahasi S; Yabe H; Maruta I; Kodera Y
    Rinsho Ketsueki; 1997 Nov; 38(11):1162-9. PubMed ID: 9423332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerance in DLA-haploidentical canine littermates following CD6-depleted marrow transplantation and donor lymphocyte transfusion.
    Zorn J; Herber M; Schwamberger S; Panzer W; Adler H; Kolb HJ
    Exp Hematol; 2009 Aug; 37(8):998-1006. PubMed ID: 19446000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors.
    van Rhee F; Savage D; Blackwell J; Orchard K; Dazzi F; Lin F; Chase A; Bungey J; Cross NC; Apperley J; Szydlo R; Goldman JM
    Bone Marrow Transplant; 1998 May; 21(10):1055-61. PubMed ID: 9632281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term molecular remission induced by donor lymphocyte infusions for recurrent acute myeloblastic leukemia after allogeneic bone marrow transplantation.
    Imoto S; Murayama T; Gomyo H; Mizuno I; Sugimoto T; Nakagawa T; Koizumi T
    Bone Marrow Transplant; 2000 Oct; 26(7):809-10. PubMed ID: 11042667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
    Min CK; Eom KS; Lee S; Kim DW; Lee JW; Min WS; Kim CC
    Bone Marrow Transplant; 2001 May; 27(9):999-1005. PubMed ID: 11436112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular remission induced by fractionated dose-escalating donor leukocyte infusion without graft-versus-host disease in a patient with chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation.
    Inai K; Wano Y; Yamamoto S; Ikebata Y; Iwasaki H; Tsutani H; Naiki H; Ueda T
    Anticancer Res; 1999; 19(6C):5631-4. PubMed ID: 10697631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acute myelogenous leukemia with mediastinal and subcutaneous emphysema following chronic GVHD after allogeneic bone marrow transplantation].
    Doki N; Irisawa H; Saito Y; Sakura T; Miyawaki S
    Rinsho Ketsueki; 2005 Sep; 46(9):1038-43. PubMed ID: 16440761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal graft-versus-host disease following HLA-mismatched donor lymphocyte infusion.
    Amrolia PJ; Rao K; Slater O; Ramsay A; Veys PA; Webb DK
    Bone Marrow Transplant; 2001 Sep; 28(6):623-5. PubMed ID: 11607779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Leukocyte transfusion as therapy of recurrent CML after allogenic bone marrow transplantation].
    Wiesneth M; Hertenstein B; Bunjes D; Novotny J; Stefanic M; Heinze B; Schreiner T; Kubanek B; Heimpel H; Arnold R
    Beitr Infusionsther Transfusionsmed; 1994; 32():276-80. PubMed ID: 9480108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
    Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R
    Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.